文献速递神经免疫

芬戈莫德两种剂量对比醋酸格拉替雷治疗复发缓解型多发性硬化:随机临床试验

Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2020-08-24

ASSESS研究为3b期随机、评估者盲、剂量盲、12个月多中心试验,纳入1064例复发缓解型多发性硬化患者,比较芬戈莫德0.5 mg、0.25 mg与醋酸格拉替雷20 mg。芬戈莫德0.5 mg较格拉替雷显著降低年化复发率(相对降低40.7%),0.25 mg相对降低14.6%无统计学意义;两种剂量均显著减少MRI病灶,不良事件比例相似。

要点

  • 芬戈莫德0.5 mg较格拉替雷20 mg显著降低ARR,相对降低40.7%。
  • 芬戈莫德0.25 mg相对降低ARR 14.6%,未达统计学显著。
  • 两种芬戈莫德剂量均显著减少新发/新增大T2和钆增强T1病灶。

核心结论

  • 在复发缓解型多发性硬化成人患者中,芬戈莫德0.5 mg临床疗效优于醋酸格拉替雷20 mg,且获益-风险优于芬戈莫德0.25 mg。

研究设计与样本

  • ASSESS为3b期多中心随机、评估者盲、剂量盲12个月临床试验,2012年8月9日至2018年4月30日进行。
  • 筛查1461例18至65岁复发缓解型多发性硬化患者,随机1064例(72.8%),平均年龄39.6岁(SD 11.0),女性792例(74.4%)。
  • 随机分组:芬戈莫德0.5 mg组352例,芬戈莫德0.25 mg组370例,醋酸格拉替雷20 mg组342例;859例(80.7%)完成研究。
  • 入组要求:既往1年至少1次记录复发或既往2年至少2次记录复发,筛查时EDSS评分0至6。

主要发现

  • 芬戈莫德0.5 mg较格拉替雷20 mg显著降低ARR,相对降低40.7%;ARR为0.15(95%CI 0.11-0.21),格拉替雷ARR为0.26(95%CI 0.20-0.34)。
  • 芬戈莫德0.25 mg相对降低ARR 14.6%,无统计学意义;ARR为0.22(95%CI 0.17-0.29)。
  • 两种芬戈莫德剂量(0.5 mg和0.25 mg)较格拉替雷20 mg均显著减少新发或新增大T2病灶和钆增强T1病灶。
  • 不良事件报告比例相似:芬戈莫德0.5 mg组312例(90.4%),0.25 mg组323例(88.3%),格拉替雷组283例(87.3%)。

临床怎么用

  • 对于复发缓解型多发性硬化成人患者,芬戈莫德0.5 mg每日一次口服可作为优于醋酸格拉替雷20 mg每日一次皮下注射的选择。
  • 芬戈莫德0.25 mg虽在MRI病灶上有效,但ARR降低未达统计学显著,其获益-风险不如0.5 mg。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Doses of fingolimod lower than 0.5 mg per day were not investigated during the fingolimod clinical development program. Whether lower doses of fingolimod might retain efficacy with fewer safety risks remains unknown. OBJECTIVE: To evaluate the efficacy and safety of fingolimod, 0.5 mg, and fingolimod, 0.25 mg, compared with glatiramer acetate and to assess whether these doses of fingolimod show superior efficacy to glatiramer acetate in adult patients with relapsing-remitting multiple sclerosis. INTERVENTIONS: Fingolimod, 0.5 mg, or fingolimod, 0.25 mg, orally once per day or glatiramer acetate, 20 mg, subcutaneously once per day. DESIGN, SETTING, AND PARTICIPANTS: The Multiple Sclerosis Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone (ASSESS) was a phase 3b multicenter randomized rater-blinded and dose-blinded 12-month clinical trial conducted between August 9, 2012, and April 30, 2018 (including the time required to recruit participants). A total of 1461 patients aged 18 to 65 years with relapsing-remitting multiple sclerosis were screened, and 1064 participants were randomized. These participants had at least 1 documented relapse during the previous year or 2 documented relapses during the previous 2 years and an Expanded Disability Status Scale score of 0 to 6 at screening. Data were analyzed between September and November 2018. MAIN OUTCOMES AND MEASURES: The superiority of the fingolimod doses was tested hierarchically, with fingolimod, 0.5 mg, vs glatiramer acetate, 20 mg, tested first, followed by fingolimod, 0.25 mg, vs glatiramer acetate, 20 mg. The primary end point was the reduction in annualized relapse rate (ARR). Magnetic resonance imaging parameters, safety, and tolerability were also assessed. RESULTS: Of 1461 adult patients screened, 1064 participants (72.8%) were randomized (mean [SD] age, 39.6 [11.0] years; 792 women [74.4%]) to 3 treatment groups: 352 participants received fingolimod, 0.5 mg, 370 participants received fingolimod, 0.25 mg, and 342 participants received glatiramer acetate, 20 mg. In total, 859 participants (80.7%) completed the study. Treatment with fingolimod, 0.5 mg, was superior to treatment with glatiramer acetate, 20 mg, in reducing ARR (40.7% relative reduction); the relative reduction with fingolimod, 0.25 mg, was 14.6%, which was not statistically significant (for fingolimod, 0.5 mg, ARR, 0.15; 95% CI, 0.11-0.21; for fingolimod, 0.25 mg, ARR, 0.22; 95% CI, 0.17-0.29; for glatiramer acetate, 20 mg, ARR, 0.26; 95% CI, 0.20-0.34). Treatment with both fingolimod doses (0.5 mg and 0.25 mg) significantly reduced new or newly enlarging T2 and gadolinium-enhancing T1 lesions compared with treatment with glatiramer acetate. Adverse events were reported in similar proportions across treatment groups (312 participants [90.4%] in the fingolimod, 0.5 mg, group, 323 participants [88.3%] in the fingolimod, 0.25 mg, group, and 283 participants [87.3%] in the glatiramer acetate group). CONCLUSIONS AND RELEVANCE: Fingolimod, 0.5 mg, demonstrated superior clinical efficacy compared with glatiramer acetate, 20 mg, and had a superior benefit-risk profile compared with fingolimod, 0.25 mg, in adult participants with relapsing-remitting multiple sclerosis. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01633112.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Cree BAC, Goldman MD, Corboy JR, et al. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2020. PMID: 32852530. doi:10.1001/jamaneurol.2020.2950

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。